You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
康哲药业(00867.HK)与全球制药公司SPARC就创新产品签订许可协议
格隆汇 11-05 19:10

格隆汇11月5日丨康哲药业(00867.HK)发布公告,2019年11月5日,集团通过全资附属公司与Sun Pharma Advanced Research Company Ltd.(“SPARC”)就其五个创新产品签订了许可协议。

根据协议的约定,集团通过全资附属公司获得了根据SPARC的知识产权和注册文件在大中华地区(包括中国大陆、香港特别行政区、澳门特别行政区和台湾)开发与商业化产品的独家的、可分许可的许可权利。协议的初始期间为产品在区域首次上市销售起算二十年,在集团全资附属公司达到协议约定的特定条件后,协议将按三年为一个区间续期。通过此次合作,集团现有的产品组合将在产品于区域上市后得以丰富及扩张。

根据披露,SPARC是一家全球制药公司,致力于通过创新的治疗和给药方式不断提高全球患者的护理标准。SPARC旨在不断降低成本并提高运营效率,以提高世界各地患者对治疗方法的可用性和可承受性。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account